Skip to main content
Erschienen in: Drugs & Aging 11/2019

24.09.2019 | Original Research Article

Prescription Synthetic Oral Cannabinoid use Among Older Adults with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study

verfasst von: Nicholas T. Vozoris, Zhan Yao, Ping Li, Peter C. Austin, Anne L. Stephenson, Sudeep S. Gill, Denis E. O’Donnell, Andrea S. Gershon, Paula A. Rochon

Erschienen in: Drugs & Aging | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Synthetic oral cannabinoids (nabilone and dronabinol) may have adverse respiratory effects. Our purpose was to describe the scope, pattern, and patient characteristics associated with incident off-label synthetic oral cannabinoid use among older adults with chronic obstructive pulmonary disease (COPD) compared to older adults without COPD.

Methods

This was a retrospective, population-based, cohort study using Ontario, Canada, heath administrative data. Individuals aged 66 years or older were included, and physician-diagnosed COPD was identified using a previously validated, highly specific algorithm. Incident off-label oral cannabinoid use was examined between April 1, 2005 and March 31, 2015. Descriptive statistics were used to describe drug use patterns. Multiple logistic regression was used to identify patient characteristics associated with incident drug use.

Results

There were 172,282 older adults with COPD and 1,068,256 older adults without COPD identified between April 1, 2005 and March 31, 2015. Incident synthetic oral cannabinoid use during this period occurred with significantly greater (p < 0.001) frequency among older adults with COPD (0.6%) versus older adults without COPD (0.3%). Compared to those without COPD, older adults with COPD used synthetic cannabinoids for significantly longer durations and more frequently at higher doses.

Conclusions

Although incident off-label oral cannabinoid use was relatively low among all older Ontarian adults, this drug class was used with greater frequency and more often in potentially concerning ways among older adults with COPD. These findings raise possible safety concerns, but further research on the respiratory safety of oral cannabinoids among individuals with COPD is needed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond). 2006;30:S13–8. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond). 2006;30:S13–8.
3.
Zurück zum Zitat Gershon AS, Wang C, Wilton AS, Raut R, To T. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population-based study. Arch Intern Med. 2010;170:560–5.PubMed Gershon AS, Wang C, Wilton AS, Raut R, To T. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population-based study. Arch Intern Med. 2010;170:560–5.PubMed
4.
Zurück zum Zitat Borge CR, Wahl AK, Moum T. Pain and quality of life with chronic obstructive pulmonary disease. Heart Lung. 2011;40:e90–101.PubMed Borge CR, Wahl AK, Moum T. Pain and quality of life with chronic obstructive pulmonary disease. Heart Lung. 2011;40:e90–101.PubMed
5.
Zurück zum Zitat Elkington H, White P, Addington-Hall J, Higgs R, Edmonds P. The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life. Palliat Med. 2005;19:485–91.PubMed Elkington H, White P, Addington-Hall J, Higgs R, Edmonds P. The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life. Palliat Med. 2005;19:485–91.PubMed
6.
Zurück zum Zitat Klink ME, Quan SF. Prevalence of reported sleep disturbances in a general adult population and their relationship to obstructive airways diseases. Chest. 1987;91:540–6.PubMed Klink ME, Quan SF. Prevalence of reported sleep disturbances in a general adult population and their relationship to obstructive airways diseases. Chest. 1987;91:540–6.PubMed
7.
Zurück zum Zitat Cormick W, Olson LG, Hensley MJ, Saunders NA. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. Thorax. 1986;41:846–54.PubMedPubMedCentral Cormick W, Olson LG, Hensley MJ, Saunders NA. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. Thorax. 1986;41:846–54.PubMedPubMedCentral
8.
Zurück zum Zitat Kim GW, Joo HJ, Park TS, et al. Vertebral compression fractures may increase mortality in male patients with chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2015;19:603–9.PubMed Kim GW, Joo HJ, Park TS, et al. Vertebral compression fractures may increase mortality in male patients with chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2015;19:603–9.PubMed
9.
Zurück zum Zitat Pascual-Guardia S, Badenes-Bonet D, Martin-Ontiyuelo C, et al. Hospital admissions and mortality in patients with COPD exacerbations and vertebral body compression fractures. Int J Chron Obstruct Pulmon Dis. 2017;12:1837–45.PubMedPubMedCentral Pascual-Guardia S, Badenes-Bonet D, Martin-Ontiyuelo C, et al. Hospital admissions and mortality in patients with COPD exacerbations and vertebral body compression fractures. Int J Chron Obstruct Pulmon Dis. 2017;12:1837–45.PubMedPubMedCentral
10.
Zurück zum Zitat Omachi TA, Blanc PD, Claman DM, et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012;13:476–83.PubMedPubMedCentral Omachi TA, Blanc PD, Claman DM, et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012;13:476–83.PubMedPubMedCentral
11.
Zurück zum Zitat Banzett RB, Henrietta E, Mulnier HE, Rosen SD, Wise RJ, Adams L. Breathlessness in humans activates insular cortex. Brain Imaging. 2000;11:2117–20. Banzett RB, Henrietta E, Mulnier HE, Rosen SD, Wise RJ, Adams L. Breathlessness in humans activates insular cortex. Brain Imaging. 2000;11:2117–20.
12.
Zurück zum Zitat Peiffer C, Poline J, Thivard L, Aubier M, Samson Y. Neural substrates for the perception of acutely induced dyspnoea. Am J Respir Crit Care Med. 2001;163:951–7.PubMed Peiffer C, Poline J, Thivard L, Aubier M, Samson Y. Neural substrates for the perception of acutely induced dyspnoea. Am J Respir Crit Care Med. 2001;163:951–7.PubMed
13.
Zurück zum Zitat Evans KC, Banzett RB, Adams L, McKay L, Frackowiak RS, Corfield DR. fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol. 2002;88:1500–11.PubMed Evans KC, Banzett RB, Adams L, McKay L, Frackowiak RS, Corfield DR. fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol. 2002;88:1500–11.PubMed
14.
Zurück zum Zitat Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87:1932–6.PubMed Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87:1932–6.PubMed
15.
Zurück zum Zitat Pickering EE, Semple SJ, Nazir MS, et al. Cannabinoid effects on ventilation and breathlessness: a pilot study of efficacy and safety. Chron Respir Dis. 2011;8:109–18.PubMed Pickering EE, Semple SJ, Nazir MS, et al. Cannabinoid effects on ventilation and breathlessness: a pilot study of efficacy and safety. Chron Respir Dis. 2011;8:109–18.PubMed
16.
Zurück zum Zitat Tashkin DP, Shapiro BJ, Frank IM. Acute pulmonary physiologic effects of smoked marijuana and oral Δ9-tetrahydrocannabinol in healthy young men. N Engl J Med. 1973;289:336–41.PubMed Tashkin DP, Shapiro BJ, Frank IM. Acute pulmonary physiologic effects of smoked marijuana and oral Δ9-tetrahydrocannabinol in healthy young men. N Engl J Med. 1973;289:336–41.PubMed
17.
Zurück zum Zitat Vachon L, Fitzgerald MX, Solliday NH, Gould IA, Gaensler EA. Single-dose effect of marijuana smoke: bronchial dynamics and respiratory center sensitivity in normal subjects. N Engl J Med. 1973;288:985–9.PubMed Vachon L, Fitzgerald MX, Solliday NH, Gould IA, Gaensler EA. Single-dose effect of marijuana smoke: bronchial dynamics and respiratory center sensitivity in normal subjects. N Engl J Med. 1973;288:985–9.PubMed
18.
Zurück zum Zitat Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and oral Δ9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. Am Rev Respir Dis. 1974;109:420–8.PubMed Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and oral Δ9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. Am Rev Respir Dis. 1974;109:420–8.PubMed
19.
Zurück zum Zitat Gray PA, Rekling JC, Bocchiaro CM, Feldman JL. Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the preBotzinger complex. Science. 1999;286:1566–8.PubMedPubMedCentral Gray PA, Rekling JC, Bocchiaro CM, Feldman JL. Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the preBotzinger complex. Science. 1999;286:1566–8.PubMedPubMedCentral
20.
Zurück zum Zitat Montandon G, Qin W, Liu H, Ren J, Greer JJ, Horner RL. PreBotzinger complex neurokinin-1 receptor-expressing neurons mediate opioid-induced respiratory depression. J Neurosci. 2011;31:1292–301.PubMedPubMedCentral Montandon G, Qin W, Liu H, Ren J, Greer JJ, Horner RL. PreBotzinger complex neurokinin-1 receptor-expressing neurons mediate opioid-induced respiratory depression. J Neurosci. 2011;31:1292–301.PubMedPubMedCentral
21.
Zurück zum Zitat Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta opioid receptors. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:354–61.PubMed Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta opioid receptors. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:354–61.PubMed
22.
Zurück zum Zitat Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2016;48:683–93.PubMed Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2016;48:683–93.PubMed
23.
Zurück zum Zitat Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323:16–21.PubMedPubMedCentral Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323:16–21.PubMedPubMedCentral
24.
Zurück zum Zitat Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5:400–11.PubMed Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5:400–11.PubMed
25.
Zurück zum Zitat Klein TW, Cabral GA. Cannabinoid-induced immune suppression and modulation of antigen presenting cells. J Neuroimmune Pharmacol. 2006;1:50–64.PubMed Klein TW, Cabral GA. Cannabinoid-induced immune suppression and modulation of antigen presenting cells. J Neuroimmune Pharmacol. 2006;1:50–64.PubMed
26.
Zurück zum Zitat Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. J COPD. 2009;6:388–94. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. J COPD. 2009;6:388–94.
27.
Zurück zum Zitat Levy R, O’Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10:67–71.PubMed Levy R, O’Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10:67–71.PubMed
28.
Zurück zum Zitat Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Drugs Aging. 2013;30:183–92.PubMed Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Drugs Aging. 2013;30:183–92.PubMed
29.
Zurück zum Zitat Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Br J Clin Pharmacol. 2016;81:161–70.PubMed Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Br J Clin Pharmacol. 2016;81:161–70.PubMed
31.
Zurück zum Zitat Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Questionable prescribing for elderly patients in Quebec. CMAJ. 1994;150:1801–9.PubMedPubMedCentral Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Questionable prescribing for elderly patients in Quebec. CMAJ. 1994;150:1801–9.PubMedPubMedCentral
32.
Zurück zum Zitat Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–52.PubMedPubMedCentral Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–52.PubMedPubMedCentral
33.
Zurück zum Zitat Hurst JR, Vestbo J, Anzueto A, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38.PubMed Hurst JR, Vestbo J, Anzueto A, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38.PubMed
34.
Zurück zum Zitat Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996;154:959–67.PubMed Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996;154:959–67.PubMed
35.
Zurück zum Zitat O’Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2008 update—highlights for primary care. Can Respir J. 2008;15S:1A–8A. O’Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2008 update—highlights for primary care. Can Respir J. 2008;15S:1A–8A.
37.
Zurück zum Zitat Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016;7:CD011694. Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016;7:CD011694.
38.
Zurück zum Zitat Fitzcharles MA, Baerwald C, Ablin J, Häuser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz. 2016;30:47–61. Fitzcharles MA, Baerwald C, Ablin J, Häuser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz. 2016;30:47–61.
39.
Zurück zum Zitat Meng H, Johnston B, Englesakis M, Moulin DE, Bhatia A. Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2017;125:1638–52.PubMed Meng H, Johnston B, Englesakis M, Moulin DE, Bhatia A. Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2017;125:1638–52.PubMed
40.
Zurück zum Zitat Moulin D, Boulanger A, Clark AJ, Canadian Pain Society, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328–35.PubMedPubMedCentral Moulin D, Boulanger A, Clark AJ, Canadian Pain Society, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328–35.PubMedPubMedCentral
41.
Zurück zum Zitat Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110:604–10.PubMed Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110:604–10.PubMed
42.
Zurück zum Zitat Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain. 2012;153:2073–82.PubMed Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain. 2012;153:2073–82.PubMed
43.
Zurück zum Zitat Abdallah SJ, Smith BM, Ware MA, et al. Effect of vaporized cannabis on exertional breathlessness and exercise endurance in advanced chronic obstructive pulmonary disease: a randomized controlled trial. Ann Am Thorac Soc. 2018;15:1146–58.PubMed Abdallah SJ, Smith BM, Ware MA, et al. Effect of vaporized cannabis on exertional breathlessness and exercise endurance in advanced chronic obstructive pulmonary disease: a randomized controlled trial. Ann Am Thorac Soc. 2018;15:1146–58.PubMed
44.
Zurück zum Zitat Vozoris NT, Leung RS. Sedative medication use: prevalence, risk factors, and associations with body mass index using population-level data. Sleep. 2011;34:869–74.PubMedPubMedCentral Vozoris NT, Leung RS. Sedative medication use: prevalence, risk factors, and associations with body mass index using population-level data. Sleep. 2011;34:869–74.PubMedPubMedCentral
45.
Zurück zum Zitat Kirby M, Denihan A, Bruce I, Radic A, Coakley D, Lawlor BA. Benzodiazepine use among the elderly in the community. Int J Geriatr Psychiatry. 1999;14:280–4.PubMed Kirby M, Denihan A, Bruce I, Radic A, Coakley D, Lawlor BA. Benzodiazepine use among the elderly in the community. Int J Geriatr Psychiatry. 1999;14:280–4.PubMed
Metadaten
Titel
Prescription Synthetic Oral Cannabinoid use Among Older Adults with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study
verfasst von
Nicholas T. Vozoris
Zhan Yao
Ping Li
Peter C. Austin
Anne L. Stephenson
Sudeep S. Gill
Denis E. O’Donnell
Andrea S. Gershon
Paula A. Rochon
Publikationsdatum
24.09.2019
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 11/2019
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-019-00707-3

Weitere Artikel der Ausgabe 11/2019

Drugs & Aging 11/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.